Loading...
•
Jun 30, 2021
Crinetics Q2 2021 Earnings Report
Crinetics Pharmaceuticals reported financial results for the second quarter of 2021 and provided a corporate update.
Key Takeaways
Crinetics Pharmaceuticals reported a net loss of $26.1 million for the second quarter of 2021. The company saw advancements across its pipeline, including the commencement of dosing in the Phase 3 PATHFNDR-1 trial of paltusotine in acromegaly and the announcement of data from CRN04894’s Phase 1 program.
Commenced dosing in Phase 3 PATHFNDR-1 study.
Reported positive data from single-ascending dose (SAD) cohorts of first-in-human study of CRN04894, demonstrating dose-dependent reductions in basal cortisol levels.
Strengthened balance sheet with successful common stock offerings, raising gross proceeds of approximately $75.0 million in April and $15.0 million in August.
Appointed Garlan Adams as General Counsel.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...